Table 4 Relative risk (95%CI) for contralateral breast cancer according to treatment of first breast cancer among 5-year breast cancer survivors in the SEER cohort.

From: Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors

  

Outcome

Population

Treatment

All Contralateral Breast Cases

Observed

RRa

95%CI

P-valueb

All first breast cancer

Radiotherapy

No/Unknownc

4599

1

  

Yes

5871

1.07

1.03–1.12

<0.001

Hormone therapy

No/Unknownc

6596

1

  

Yes

3874

0.92

0.88–0.96

<0.001

ER+ first breast cancer

Hormone therapy

No/Unknownc

3511

1

  

Yes

3421

0.95

0.90–0.99

0.039

Radiotherapy with HT

No/Unknownc

1021

1

  

Yes

2400

1.03d

0.95–1.11

0.489

Radiotherapy without HT

No/Unknownc

1784

1

  

Yes

1727

1.09d

1.02–1.17

0.010

  

ER+ Contralateral Breast Cases

All first breast cancer

Radiotherapy

No/Unknownc

3245

1

  

Yes

4345

1.07

1.02–1.12

0.006

Hormone therapy

No/Unknownc

4618

1

  

Yes

2972

0.96

0.91–1.01

0.090

ER+ first breast cancer

Hormone therapy

No/Unknownc

2714

1

  

Yes

2679

0.94

0.89-0.99

0.035

Radiotherapy with HT

No/Unknownc

785

1

  

Yes

1894

1.03e

0.94–1.12

0.414

Radiotherapy without HT

No/Unknownc

1348

   

Yes

1366

1.12e

1.04–1.21

0.004

  

ER- Contralateral Breast Cases

All first breast cancer

Radiotherapy

No/Unknownc

799

1

  

Yes

1039

1.12

1.01–1.23

0.028

Hormone therapy

No/Unknownc

1248

1

  

Yes

590

0.84

0.76–0.93

<0.001

ER+ first breast cancer

Hormone therapy

No/Unknownc

401

1

  

Yes

481

1.15

0.99–1.32

0.054

Radiotherapy with HT

No/Unknownc

141

1

  

Yes

340

1.01 f

0.83–1.24

0.69

Radiotherapy without HT

No/Unknownc

203

1

  

Yes

198

1.10 f

0.89–1.34

0.379

  1. BC breast cancer, ER oestrogen receptor.
  2. aRelative risk estimated using Poisson regression, adjusted for year of diagnosis and age at diagnosis, grade, tumour size, radiotherapy, chemotherapy, hormone therapy and grade and tumour size as appropriate.
  3. bLikelihood ratio test for heterogeneity of relative risks.
  4. cTreatment variables in SEER are classified as “yes” or “no/unknown” since SEER cannot accurately distinguish between “no treatment” and “unknown if patients received treatment”.
  5. dP-difference=0.28 between the RRs for radiotherapy with and without hormone therapy.
  6. eP-difference=0.16 between the RRs for radiotherapy with and without hormone therapy.
  7. fP-difference=0.34 between the RRs for radiotherapy with and without hormone therapy.